Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programme

被引：0
|
作者：
Vermeire, S. [1 ]
Rubin, D. T. [2 ]
Regueiro, M. D. [3 ]
Takeuchi, K. [4 ]
Walsh, A. [5 ]
Kotze, P. G. [6 ]
Charabaty, A. [7 ]
Goetsch, M. [8 ]
Lazin, K. [8 ]
Wu, J. [9 ]
Tsamos, G. [10 ]
Segovia, M. [11 ]
Branquinho, D. [11 ]
Danese, S. [12 ,13 ]
机构：
[1] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[2] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA
[3] Cleveland Clin, Dept Gastroenterol Hepatol & Nutr, Cleveland, OH USA
[4] Tsujinaka Hosp Kashiwanoha, IBD Ctr, Dept Gastroenterol, Kashiwa, Chiba, Japan
[5] Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, England
[6] Pontificia Univ Catolica Parana PUCPR, IBD Outpatient Clin, Colorectal Surg Unit, Curitiba, Brazil
[7] Johns Hopkins Sch Med, Div Gastroenterol & Hepatol, Washington, DC USA
[8] Pfizer AG, Zurich, Switzerland
[9] Pfizer Inc, Cambridge, MA USA
[10] Pfizer Thessaloniki, Thessaloniki, Cent Macedonia, Greece
[11] Pfizer Inc, New York, NY USA
[12] IRCCS San Raffaele Hosp, Milan, Italy
[13] Univ Vita Salute San Raffaele, Div Gastroenterol & Endoscopy, Milan, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.0057
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP018
引用
收藏
页码：i115 / i117
页数：3
相关论文
共 50 条
  • [41] Etrasimod for the treatment of ulcerative colitis: analysis of infection rates from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials
    Regueiro, M.
    Siegmund, B.
    Yarur, A.
    Steinwurz, F.
    Gecse, K. B.
    Goetsch, M.
    Bhattacharjee, A.
    Wu, J.
    Green, J.
    McDonnell, A.
    Crosby, C.
    Lazin, K.
    Branquinho, D. Ferreira
    Modesto, I.
    Abreu, M. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 689 - 690
  • [42] The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme
    Farraye, Francis A.
    Qazi, Taha
    Kotze, Paulo G.
    Moore, Gregory T.
    Mundayat, Rajiv
    Lawendy, Nervin
    Sharma, Puza P.
    Judd, Donna T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (04) : 429 - 440
  • [43] EFFICACY AND SAFETY OF LONG-TERM TREATMENT WITH FILGOTINIB FOR ULCERATIVE COLITIS: DATA FROM SELECTIONLTE
    Morison, Ben
    Feagan, Brian
    Matsuoka, Katsuyoshi
    Rogler, Gerhard
    Faes, Margaux
    Oortwijn, Alessandra
    de Haas, Angela
    Rudolph, Christine
    Patel, Haridarshan
    Peyrin-Biroulet, Laurent
    GUT, 2022, 71 : A60 - A61
  • [44] Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
    Cohen, Stanley B.
    Tanaka, Yoshiya
    Mariette, Xavier
    Curtis, Jeffrey R.
    Lee, Eun Bong
    Nash, Peter
    Winthrop, Kevin L.
    Charles-Schoeman, Christina
    Thirunavukkarasu, Krishan
    DeMasi, Ryan
    Geier, Jamie
    Kwok, Kenneth
    Wang, Lisy
    Riese, Richard
    Wollenhaupt, Juergen
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (07) : 1253 - 1262
  • [45] Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study
    Vermeire, Severine
    Chiorean, Michael
    Panes, Julian
    Peyrin-Biroulet, Laurent
    Zhang, Jinkun
    Sands, Bruce E.
    Lazin, Krisztina
    Klassen, Preston
    Naik, Snehal U.
    Cabell, Christopher H.
    Sandborn, William J.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (06): : 950 - 959
  • [46] Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS Study
    Chiorean, Michael
    Vermeire, Severine
    Panes, Julian
    Peyrin-Biroulet, Laurent
    Zhang, Jinkun
    Sands, Bruce E.
    Lazin, Krisztina
    Cabell, Chris H.
    Naik, Snehal U.
    Klassen, Preston
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S445 - S446
  • [47] Response and remission rates with up to 3 years of vedolizumab treatment in patients with ulcerative colitis
    Loftus, E. V., Jr.
    Colombel, J. -F.
    Previtali, A.
    Smyth, M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S58 - S59
  • [48] Response and Remission Rates With up to 3 Years of Vedolizumab Treatment in Patients with Ulcerative Colitis
    Loftus, Edward V.
    Colombel, Jean-Frederic
    Previtali, Alessandro
    Smyth, Michael D.
    GASTROENTEROLOGY, 2016, 150 (04) : S805 - S805
  • [49] Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
    D'Amico, Ferdinando
    Parigi, Tommaso Lorenzo
    Fiorino, Gionata
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
  • [50] Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center
    Cohen, Nathaniel A.
    Choi, David
    Garcia, Nicole
    Choi, Natalie K.
    Picker, Emma
    Cleveland, Noa Krugliak
    Cohen, Russell D.
    Dalal, Sushila R.
    Pekow, Joel
    Rubin, David T.
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (02) : 579 - 587
12345